Annual reports

Kranjec C, Eilertsen IA, Nunes L, Moosavi SH, Berg KCG, Eknæs M, Hektoen M, Niederdorfer B, Lind GE, Skotheim RI, Sveen A, Lothe RA (2026)
Common gene mutations in 103 authenticated colorectal cancer cell lines
Oncogenesis (in press)
DOI 10.1038/s41389-026-00599-0, PubMed 41593049

Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA (2026)
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer
Breast, 86, 104704 (in press)
DOI 10.1016/j.breast.2026.104704, PubMed 41581361

Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG (2026)
Transcription termination counteracts DNA damage after WEE1 inhibition
Nucleic Acids Res, 54 (3)
DOI 10.1093/nar/gkaf1487, PubMed 41569153

Morken S, Langer SW, Hjortland GO, Sundlöv A, Hofsli E, Ladekarl M, Tabaksblat E, Vestermark LW, Svensson J, Knigge U, Nunes L, Glimelius B, Pfeiffer P, Aasebø K, Assmus J, Vassella E, Lothe IMB, Couvelard A, Perren A, Knappskog S, Sorbye H (2026)
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
Int J Cancer (in press)
DOI 10.1002/ijc.70367, PubMed 41642024

Skrede OJ, Pradhan M, Isaksen MX, Hveem TS, Vlatkovic L, Nesbakken A, Lindemann K, Kristensen GB, Kasius J, Zeimet AG, Brustugun OT, Busund LR, Richardsen EH, Haug ES, Brennhovd B, Rewcastle E, Lillesand M, Kvikstad V, Janssen E, Kerr DJ, Liestøl K, Albregtsen F, Kleppe A (2026)
Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types
NPJ Precis Oncol (in press)
DOI 10.1038/s41698-026-01311-6, PubMed 41634087

Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR (2026)
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
ESMO Open, 11 (2), 106070 (in press)
DOI 10.1016/j.esmoop.2026.106070, PubMed 41643268